Biocure Technology Inc. · CSE:CURE.X
Biocure Technology — Investor Presentation (December 2021)
31 slides from Biocure Technology's investor presentation, December 2021
Slide 1: Front Runner in CAR-T Cell Therapy for Cancer Patients
CSE: CURE│OTCQB:BICTF│FSE:1WH CSE: CURE│OTCQB: BICTF│FSE: 1WH FRONT RUNNER IN CAR-T CELL THERAPY FOR CANCER PATIENTS Investor Presentation, December 2021 BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 1 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 2: CAR-T Technology
CSE: CURE│OTCQB:BICTF│FSE:1WH CAR-T TECHNOLOGY CSE: CURE│OTCQB: BICTF BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 2 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 3: What Is CAR-T Cell Therapy?
WHAT IS CAR-T CELL THERAPY? CSE: CURE│OTCQB:BICTF│FSE:1WH • T cells that have receptors for specific binding to CANCER BREAKTHROUGH the antigens expressed on cancer cells. by CNN, 2017 • Developed and approved for the first time as a CAR-T therapy is a therapeutic treatment method for acute leukemia
Slide 4: Structure and Principle of CAR-T Cell
STRUCTURE AND PRINCIPLE OF CAR-T CELL CSE: CURE│OTCQB:BICTF│FSE:1WH (Source: Genetic Engineering & Biotechnology News) (Source: Adaptimmune IR Materials) BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 4 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 5: CAR-T Cell Therapy Mechanism
CAR-T CELL THERAPY MECHANISM CSE: CURE│OTCQB:BICTF│FSE:1WH Uses a patient’s own immune system to fight certain types of cancer Manufactured Transduction of CAR Re-injection of CAR-T cells recognize using T cells (Chimeric Antigen CAR-T cells into the CD19 antigen on extracted from Receptor) into T c
Slide 6: BCP401: CD19 CAR-T
CSE: CURE│OTCQB:BICTF│FSE:1WH BCP401: CD19 CAR-T CSE: CURE│OTCQB: BICTF BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 6 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 7: FDA Approved CD19 CAR-T Cell Therapy
FDA APPROVED CD19 CAR-T CELL THERAPY CSE: CURE│OTCQB:BICTF│FSE:1WH • As of 2021, 4 types of CAR-T cells have been Product Target Indication Manufacturer commercialized. • All use Intravenous injection using CD19 ALL/DBCL Novartis / UPENN autologous cells. • The cost of one treatment Kymriah is about
Slide 8: Clinical Progress Trend for Upcoming CAR-T Cell Therapy
CLINICAL PROGRESS TREND FOR UPCOMING CAR-T CELL THERAPY CSE: CURE│OTCQB:BICTF│FSE:1WH • The CD19 antigen is the most powerful antigen, and many clinical studies use the CD19 antigen. • In the early stages of development, the biggest problem with CAR-T cell therapy was the side effects such as CRS. •
Slide 9: BCP401: First CAR-T Cell Therapy by Biocure Pharm
BCP401: FIRST CAR-T CELL THERAPY BY BIOCURE PHARM CSE: CURE│OTCQB:BICTF│FSE:1WH Nonclinical Toxicity / Manufacturing in GMP / Nonclinical Efficacy IND Filing Distribution Specification and Assay • Single to one toxicity • Physical chemistry and • Lenti virus • Application • Repeat permeability biolo
Slide 10: BCP401: Manufacturing Process for Biocure Pharm Drug Product
BCP401: MANUFACTURING PROCESS FOR BIOCURE PHARM DRUG PRODUCT CSE: CURE│OTCQB:BICTF│FSE:1WH 1. Patient’s blood Re-injection into body to attack and kill a cancerous cells after making CAR-T cell, using 2. PBMC isolation by DGCF • • Cell counting Cell viability the T cell extracted from patient’s bloo
Slide 11: BCP 401: Non-Clinical Development
BCP 401: NON-CLINICAL DEVELOPMENT CSE: CURE│OTCQB:BICTF│FSE:1WH Construction of Letiviral vector system Genetic transduction into T cell Efficacy test (Preclinical) Confirmation of BCP019 CAR-T therapy for leukemia on animal model test BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 11 TECHNICAL PR
Slide 12: BCP 401: Result from Research Purpose IIT Clinical Trial
BCP 401: RESULT FROM RESEARCH PURPOSE IIT CLINICAL TRIAL CSE: CURE│OTCQB:BICTF│FSE:1WH • Performed at People´s Hospital, Beijing: 63 Subjects with relapse/refractory ALL (1~25 age) • Primary Endpoint for the Efficacy Analysis • ORR evaluation within 3 mths after treatment. ORR confirmed through peri
Slide 13: BCP401: Comparison of R/R B-ALL Efficacies of CD19-Targeted CAR-T
BCP401: COMPARISON OF R/R B-ALL EFFICACIES OF CD19-TARGETED CAR-T IN VARIOUS TRIALS CSE: CURE│OTCQB:BICTF│FSE:1WH Institution # of Pts Median age (range) Disease-related outcomes • The CD19 technology reported Children’s Hospital of 30 (25 children, Pediatric: ALL 11 (5-22) • CR: 90% (MRD-negative i
Slide 14: BCP402: ROR1 CAR-T
CSE: CURE│OTCQB:BICTF│FSE:1WH BCP402: ROR1 CAR-T CSE: CURE│OTCQB: BICTF BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 14 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 15: CLL (Chronic Lymphocytic Leukemia)
CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) CSE: CURE│OTCQB:BICTF│FSE:1WH • Most common in adults and accounts for approximately 40% of all leukemia. Incident cases of Chronic CLL in 2020 • The median age of diagnosis is 70 years, and twice as many men develop CLL compared to women. • While no definitive cau
Slide 16: Top-Selling Drugs of Treatment for CLL
TOP-SELLING DRUGS OF TREATMENT FOR CLL CSE: CURE│OTCQB:BICTF│FSE:1WH Brand Name Global Sales Company Approval Target (generic name) (2019) Imbruvica AbbVie and Johnson 2013 BTK $7.24B (ibrutinib) & Johnson CD20 Biogen and Roche/ Rituxan (rituximab) 1997 Monoclonal $6.62B Genentech Antibody Venclexta
Slide 17: Target Options of Treatment for CLL Under Development
TARGET OPTIONS OF TREATMENT FOR CLL UNDER DEVELOPMENT CSE: CURE│OTCQB:BICTF│FSE:1WH • After CD20s, other promising targets Top Targets for Drug Development Against CLL (Number of drugs) under evaluation include BTK, PIK3CD, and Bcl2. 110 • CD37, CRBN and CD22 are targets being evaluated less in CLL
Slide 18: BCP402 as Treatment for Chronic Leukemia (CLL)
BCP402 AS TREATMENT FOR CHRONIC LEUKEMIA (CLL) CSE: CURE│OTCQB:BICTF│FSE:1WH • ROR1 is a CLL-specific antigen, and its expression rate is very low in normal cells. • It has high specificity and safety. • The development of BCP402 can increase the response rate and reduce side effects. • The use of R
Slide 19: Upcoming CAR-T Projects
CSE: CURE│OTCQB:BICTF│FSE:1WH UPCOMING CAR-T PROJECTS CSE: CURE│OTCQB: BICTF BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 19 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 20: BCP's CAR Platform
BCP’S CAR PLATFORM CSE: CURE│OTCQB:BICTF│FSE:1WH - Biocure demonstrated with the BCP401 (CD19 CAR-T) project the ability to design, create and develop effective and powerful CAR-T therapy. - We are developing CAR-T for the therapy of CLL (BCP402) and solid tumors (BCP403). - We are currently designi
Slide 21: Biocure
CSE: CURE│OTCQB:BICTF│FSE:1WH BIOCURE BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │ 21 TECHNICAL PRESENTATION – DECEMBER 2021 FSE:1WH)
Slide 22: Why Invest?
WHY INVEST? CSE: CURE│OTCQB:BICTF│FSE:1WH Accomplished Board Low valuation Biocure’s has an extremely solid board of directors, At sub C$20m market cap, huge upside potential exists advisory board and industry experts to enable it to for shareholders upon rerating of its shares execute on its growth
Slide 23: Core Competencies
CORE COMPETENCIES CSE: CURE│OTCQB:BICTF│FSE:1WH 1. Possesses innovative 3. Established 4. Overseas CAR-T development 2. R&D network overseas clinical commercialization capabilities based on CD19 established CAR-T experience network network established For future second-generation Planning for innova
Slide 24: Business Strategy
BUSINESS STRATEGY CSE: CURE│OTCQB:BICTF│FSE:1WH Productization Innovative CAR-T series development and patent application in the shortest strategy time: chronic leukemia, solid tumors. Preparing for clinical development of BCP402 (ROR1 CAR-T) for the treatment of chronic leukemia (CLL) with a clinic
Slide 25: Plans for Product Development and Commercialization
PLANS FOR PRODUCT DEVELOPMENT AND COMMERCIALIZATION CSE: CURE│OTCQB:BICTF│FSE:1WH Program Indication 2022 2023 2024 2025 2026 • Patent filed • Phase 1 clinical trial • Phase 2 clinical trial BCP402 CLL • Preclinical progress (Europe) (Europe) • IND application • Patent filed • Phase 1 clinical trial
Slide 26: Corporate History to Date
CORPORATE HISTORY TO DATE CSE: CURE│OTCQB:BICTF│FSE:1WH Substantial investment and business progression made 2022 Phase I CLL clinical trial planned 2021 Dual listing on Frankfurt Exchange 2018 Completed 2020 2017 pre-clinical trial of MOU with Announced CAR-T CAR-T cell Therapy S&B Biopharma, 2016
Slide 27: 12 Month Focus & Outlook
12 MONTH FOCUS & OUTLOOK CSE: CURE│OTCQB:BICTF│FSE:1WH The Company continues to build financial value within Cancer Treatment through two ways; • Development of it’s own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies
Slide 28: Historic Value Estimation and Potential Comparison to Early Clinical Stage Companies
HISTORIC VALUE ESTIMATION AND POTENTIAL CSE: CURE│OTCQB:BICTF│FSE:1WH IPO at Non-Clinical Stage Current Market Cap Company Listed Current Stage (mUSD) (mUSD) Autolus Therapeutics NASDAQ 150 520 Ph 1 Adaptimmune NASDAQ 191 950 Ph2 Therapeutics Cabaletta Bio NASDAQ 75 270 Ph1 Kite Pharma N/A 128 Acqui
Slide 29: Capital Structure
CAPITAL STRUCTURE CSE: CURE│OTCQB:BICTF│FSE:1WH Share Structure Options Outstanding *as of Nov 5th 2021 Expiry Date Exercise Price Amount of Options Outstanding Shares 106,621,158 Apr. 2022 $0.38 300,000 Share Price $0.15 Feb. 2024 $0.30 6,020,000 Warrants 9,051,272 Jul. 2024 $0.30 1,250,000 Outstan
Slide 30: Board of Directors and Management
BOARD OF DIRECTORS AND MANAGEMENT CSE: CURE│OTCQB:BICTF│FSE:1WH Experienced leadership team Dr. Sang Mok Lee Dr. Bjorn Cochlovius Mr. Konstantin Lichtenwald Mr Collin (Sang Goo) Kim Mr. Berkan Unal Dr. Danny Joh CEO & Founder, Director President CFO, Director Director Director Director • President a
Slide 31: Contact
CSE: CURE│OTCQB:BICTF│FSE:1WH CSE: CURE│OTCQB:BICTF│FSE:1WH Website: https://biocuretech.com/ Email : info@biocuretech.com Address: 300-1055 West Hastings Street Vancouver, BC V6E 2E9 Canada Phone +1 604-609-7146 Investor Relations (North America) Investor Relations (Europe) Purple Crown Communicati
Biocure Technology — Investor Presentation (December 2021) on 6ix